Immunotherapy Drugs Market Size to Reach $227.6 Billion by 2023

  • Published: November 2018

Immunotherapy drugs market is forecasted to attain a size of $227.6 billion by 2023, according to P&S Intelligence.

With the thriving demand and increase in the development of monoclonal antibodies (mAbs), increasing prevalence of chronic diseases, and growing implementation of target therapy, the market is expected to progress significantly in the coming years.

Insights into market segments

Based on type, the immunotherapy drugs market has been categorized into checkpoint inhibitors and vaccines. Among these two, the checkpoint inhibitors category generated higher revenue in the historical period, and is expected to generate more than $100.0 billion revenue by 2023. Increasing development of mAbs, and rise in the adoption of chimeric antigen receptor (CAR) T-cell therapy are the major factors contributing to the larger share of this category.

Vaccines are further sub-categorized on the basis of type and brand. The two types of vaccines available in the immunotherapy drugs market are preventive and therapeutic vaccines. Among these, preventive vaccines held a larger share in the market. Among the various brand of vaccines available, Prevnar/Prevenar 13 is one of the bestseller vaccines brands and generated the highest revenue of $5.6 billion in the market, in 2017.

Immunotherapy drugs are majorly used for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. Cancer held the largest share in the immunotherapy drugs market for therapy area, in 2017. This can be ascribed to the increasing prevalence of cancer across the globe.

On the basis of end user, the immunotherapy drugs market has been categorized into hospitals and clinics, and individuals. Of these, hospitals and clinics are expected to demonstrate faster growth, at a CAGR of 14.0% during the forecast period. This can be attributed to the increasing patient base in hospitals and clinics, which leads to high requirement of immunotherapy drugs in this end-user category.

Browse report overview with 91 tables and 62 figures spread through 207 pages and detailed TOC on "Immunotherapy Drugs Market by Type (Checkpoint Inhibitors [Brand {Humira, Rituxan/MabThera, Herceptin, Remicade, Enbrel}], Vaccines [Type {Preventive, Therapeutic}, Brand {Prevnar/Prevenar 13, Gardasil, ProQuad, Rotarix}]), by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases), by End User (Hospitals & Clinics, Individuals), by Geography (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2013–2023" at:

Immunotherapy drugs market to witness fastest growth in Asia-Pacific (APAC)

The APAC immunotherapy drugs market is expected to observe the fastest growth, at a CAGR of 14.3% during the forecast period, mainly on account of increasing healthcare expenditure for the improvement of healthcare infrastructure and growing research and development (R&D) activities in the region.

Market players are expanding their portfolio through new product launches and received approvals

The players in the immunotherapy drugs industry are enhancing their product portfolio through product launches and also have received approvals from government organizations for its application. For instance, in September 2018, Sanofi received approval for Libyato for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, who are not candidates for curative surgery or curative radiation.

Likewise, in September 2018, AstraZeneca plc received the U.S. Food and Drug Administration (USFDA) approval for Lumoxiti (moxetumomab pasudotox-tdfk). AstraZeneca plc developed Lumoxiti together with MedImmune LLC, for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL), who have received at least two prior systemic therapies, including purine nucleoside analog treatment.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, Celgene Corporation, and Pfizer Inc. are other key players present in the immunotherapy drugs market.

The scope of study also includes the epidemiology coverage for cancer, autoimmune and inflammatory diseases, and infectious diseases; pricing and reimbursement scenario for immunotherapy drugs; research and funding initiatives for immunotherapy drugs; and list of immunotherapy drugs in the pipeline of the key market players.


By Type

  • Checkpoint Inhibitors
    • By brand
      • Humira
      • Rituxan/MabThera
      • Herceptin
      • Remicade
      • Enbrel
      • Others
  • Vaccines
    • By type
      • Preventive vaccines
      • Therapeutic vaccines
    • By brand
      • Prevnar/Prevenar 13
      • Gardasil
      • ProQuad
      • Rotarix
      • Others

Market Segmentation by Therapy Area

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases

Market Segmentation by End User

  • Hospitals and Clinics
  • Individuals

Market Segmentation by Geography

  • North America Immunotherapy Drugs Market
    • By therapy area
    • By end user
    • By country – U.S. and Canada
  • Europe Immunotherapy Drugs Market
    • By therapy area
    • By end user
    • By country – Germany, U.K., France, Italy, Spain, and Rest of Europe
  • Asia-Pacific (APAC) Immunotherapy Drugs Market
    • By therapy area
    • By end user
    • By country – Japan, China, India, Australia, South Korea, and Rest of APAC
  • Latin America (LATAM) Immunotherapy Drugs Market
    • By therapy area
    • By end user
    • By country – Brazil, Mexico, and Rest of LATAM
  • Middle East and Africa (MEA) Immunotherapy Drugs Market
    • By therapy area
    • By end user
    • By country – Saudi Arabia, South Africa, and Rest of MEA